arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Eton Pharmaceuticals, Inc.

ETON
$44.57 ▼ -1.56 (-3.38%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Eton Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2B
Dividend Yield
Revenue Growth 40.4%
Op. Margin 9.9%
ROIC 4.8%
FCF / Share $0.27
Trailing P/E 742.8x
Price / Book 39.8x
FCF Yield 0.6%
Debt / Equity 0.62
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$24.27M
↑ +40.4%
Net Income Profit after all expenses
$1.55M
↑ +4.8%
Operating Margin Operating profit as % of sales
9.9%
↓ -14.1% 26th
FCF / Share Free cash flow per share
$0.27
↑ +245.6%
Long-Term Debt Long-term obligations
$18.94M
↓ -13.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
38
Returns
29
Financial Health
41
Cash Quality
6

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 35 quarters